Ford CEO Jim Hackett is stepping down, and will be replaced by current COO Jim Farley. Yahoo Finance’s On the Move panel discusses.

from Yahoo Finance https://ift.tt/3ka0lP1

Lakewood Capital Management recently released its Q2 2020 Investor Letter, a copy of which you can download here. In the letter, among other things, the fund reported a net profit of 10.7% for Q2 2020. You should check out Lakewood Capital’s top 5 stock picks for investors to buy right now, which could be the […]

from Yahoo Finance https://ift.tt/31gv7wR

Lakewood Capital Management recently released its Q2 2020 Investor Letter, a copy of which you can download here. In the letter, among other things, the fund reported a net profit of 10.7% for Q2 2020. You should check out Lakewood Capital’s top 5 stock picks for investors to buy right now, which could be the […]

from Yahoo Finance https://ift.tt/33p2K2b

Disgruntled employees at games developer Blizzard Entertainment — some of whom reportedly earn only minimum wage — have shared their compensation details in an internal document, hoping to spur the company to pay workers more fairly. According to a Bloomberg report, a company employee created a spreadsheet and encouraged others to share their compensation info […]

from Yahoo Finance https://ift.tt/3ibK8qv

Auto industry disruptor Nikola (NKLA) will report 2Q earnings today after the bell. In yesterday’s tech rally, the electric heavy-truck maker surged by 22%.Was the surge in anticipation of a “home run” report? Hardly. In fact, results wise there will be very little to tell investors, as Nikola has no product yet and isn’t expected to have anything to sell until the second half of next year at the earliest.However, there were several reasons for the rally. One was a note to investors from Deutsche Bank, in which analyst Emmanuel Rosner added the company to its short-term Catalyst Call Buy List.Rosner recommends investors pull the trigger on NKLA shares in anticipation of updates from Executive Chairman and founder Trevor Milton.Maybe Nikola has little to show for now, but Milton has taken a leaf out of the mercurial entrepreneur playbook. The founder has already exhibited all the hallmarks of an adept showman, with a flair for headline grabbing antics. The latest of which was a tweet reassuring investors as to the health of Nikola’s balance sheet. The savvy move helped push the share price higher, too.So, what does Rosner expect Milton to reveal that instigated the Buy Idea?“We see catalysts occurring with Nikola’s earnings report this week,” the analyst said, “Including: customers for its BEV truck; commercial partner for the hydrogen stations; OEM manufacturing partner; and an updated Badger reservations count . Beyond it, some or all of the above company updates could come in the next couple months. We are targeting a 10-20% return for this Catalyst Call.” It will be interesting to see how much battery power there will be left to push shares higher after yesterday’s surge. To this end, Rosner has a $54 price target on the stock, implying there’s a 42% upside in the cards. Additionally, as mentioned, Rosner’s Hold rating makes a switch to a “short term” Buy. (To watch Rosner’s track record, click here)There’s similar sentiment among Rosner’s colleagues. 2 Buys and Holds each, add up to a Moderate Buy consensus rating. At $56.67, the average price target could provide gains of 55% over the coming months. (See Nikola stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

from Yahoo Finance https://ift.tt/2DmirN9

Disney is set to report earnings after the markets close today. Yahoo Finance’s Ines Ferre has a preview.

from Yahoo Finance https://ift.tt/30pfqV1

What are the largest technology ETFs? Technology companies are dominating the stock market, and of course, the world. With the rise of artificial intelligence, machine learning, and other futuristic technologies, tech companies are expected to play an even bigger role in our lives. If you are bullish on the tech sector, technology ETFs are one […]

from Yahoo Finance https://ift.tt/39PXTbz

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

from Yahoo Finance https://ift.tt/33nijaA

Goldman Sachs on Monday upgraded pharma giant Merck & Co. to Buy from Hold, citing its strong pipeline and cancer drug Keytruda.Goldman analyst Terence Flynn lifted Merck's (MRK) price target to $105 (27.2% upside potential) from $91, saying “the market seems to be underappreciating a potential opportunity of between $13 billion and $18 billion in pipeline assets". Flynn also believes “Keytruda loss of exclusivity tail risk” is already priced into the stock.The analyst added that “Merck has developed several earlier stage cancer assets that can be used in combination with Keytruda or in patients who do not respond to Keytruda”. He views “the stock's risk/reward as attractive heading into a number of upcoming readouts later this year and into next for cancer, HIV and COVID-19”. Further, Merck might combine with another longer-acting drug “to create a long-acting injectable formulation that could represent the next innovation in the HIV market,” according to Flynn.The company, which is in the process of developing two vaccines along with a COVID-19 vaccine, expects a gradual recovery in the third quarter.Currently, the Street has a cautiously optimistic outlook on the stock. The Moderate Buy analyst consensus is based on 5 Buys and 3 Holds. The average price target of $93.5 implies an upside potential of 13.3%. (See MRK stock analysis on TipRanks).Related News: Sorrento’s New COVID-19 Test Could Be a Game Changer, Says 5-Star Analyst After Amazon Trounces 2Q Estimates, 5-Star Analyst Says There’s More to Come Challenges Ahead, but Facebook Stock Will March On, Says 5-Star Analyst More recent articles from Smarter Analyst: * Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients * Merck, Hanmi Seal Licence Deal For Fatty Liver Disease Therapy * TikTok Parent ByteDance Accuses Facebook Of ‘Plagiarism And Smear’ * McKesson Beats 2Q Estimates, UBS Lifts PT

from Yahoo Finance https://ift.tt/33rbrZN

Shares of Cirrus Logic fell 3.1% in extended market trading on Monday as the company expects 2Q sales to be lower than analysts' estimates. While 2Q revenue guidance was disappointing, its 1Q earnings crushed analysts' estimates.Cirrus Logic's (CRUS) adjusted EPS jumped 51.4% to $0.53 year-on-year exceeding analysts’ estimates of $0.30. Moreover, revenues grew 1.8% to $242.6 million year-over-year and surpassed Street estimates of $225.6 million.The audio chip-maker anticipates 2Q revenues between $290 million and $330 million, which is lower than the Street estimate of $315 million at mid-point. Moreover, Cirrus Logic anticipates a decline in the average selling price across some products during the quarter.On June 22, Barclays analyst Blayne Curtis downgraded Cirrus Logic to Sell from Hold and lowered the price target to $60 (19.5% downside potential) down from $75. Curtis said he sees "downside to estimates given the likely loss of in-box earbuds this year and loss of its smart codec at Samsung."Overall, CRUS analysts have a cautiously optimistic Moderate Buy consensus on the stock. The average price target of $77.67 implies upside potential of 4.3%. (See CRUS stock analysis on TipRanks).Related News: Church & Dwight Jumps 7% on 2Q Earnings; Analyst Sees More Upside Ahead Molson Coors Delivers Q2 Earnings Beat Despite Covid-19 Fallout Newell Brands Drops 7% On Dim Outlook More recent articles from Smarter Analyst: * Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients * Merck, Hanmi Seal Licence Deal For Fatty Liver Disease Therapy * TikTok Parent ByteDance Accuses Facebook Of ‘Plagiarism And Smear’ * McKesson Beats 2Q Estimates, UBS Lifts PT

from Yahoo Finance https://ift.tt/30pAb2I